Patent ID: 8679769

Claim:
A non-invasive in vitro method comprising a) measuring one or more biomarkers selected from the group of Actin cytoplasmic 2, Adenosylhomocysteinase, Adenylosuccinate synthetase isozyme 2, ADP-sugar pyrophosphatase, Alcohol dehydrogenase [NADP+], Aldehyde dehydrogenase 1A3, Alpha-amylase 1 precursor, Annexin A1, Apolipoprotein A-1 precursor, Beta-actin, Beta-2-glycoprotein 1 precursor, Bisphosphoglycerate mutase, Catalase, Chloride intracellular channel protein 4, Coiled-coil domain containing protein 94, Cytosol aminopeptidase, F-actin capping protein subunit beta, Ferritin heavy chain, Ferritin light chain, Flavin reductase, Galectin-1, Glutathione transferase omega-1, Glutathione S-transferase, Glycodelin precursor, Lactoylglutathione lyase, Heat-shock protein beta 1, Hemoglobin subunit beta, Leukocyte elastase inhibitor, Moesin, Peptidyl-prolyl cis-trans isomerase A, Phosphoglycerate mutase I, Phosphomevalonate kinase, Poly(rC)-binding protein 1, Pyridoxine-5′-phosphate oxidase, Proteasome subunit beta type 3, 26S proteasome non-ATPase regulatory subunit 7, 26S proteasome non-ATPase regulatory subunit 10, 14-3-3 protein beta/alpha, 14-3-3 protein gamma, 14-3-3 protein sigma, 14-3-3 protein theta, 14-3-3 protein zeta/delta, Rho GDP-dissotiation inhibitor 1, Rho GDP-dissotiation inhibitor 2, Ribose-phosphate pyrophosphokinase II, Septin-11, Serine/threonine-protein kinase Nek7, Sialic acid synthase, Translationally-controlled tumor protein, Tubulin beta chain and WD repeat protein 1 in a sample from an individual, and b) comparing the measurements of the one or more biomarkers in the sample with the measurement of the one or more biomarkers in a normal sample, wherein an alteration in the measurement of the one or more biomarkers compared to the measurement of the one or more biomarkers in the normal sample is indicative of endometriosis.